Interventional Pain Specialists of Bowling Green PLC

Interventional Pain Specialists of Bowling Green PLC was paid $10.61M by Medicaid between Jan 2018 and Nov 2023, across 53 billing codes. Its largest line is G0480, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed — 22% of everything it billed.

Compared with peers

Next to other Clinical Psychologist providers in Kentucky

Rank by total paid#3 of 31

Median peer was paid$229K

This provider vs. median46×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	90,121	$2.31M
2019	80,778	$1.93M
2020	52,645	$1.71M
2021	52,621	$1.93M
2022	47,906	$1.67M
2023	31,999	$1.06M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	22%	37,157	33,258	$2.37M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	18%	47,046	41,814	$1.90M
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	11%	47,259	42,864	$1.17M
99214	Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	11%	31,226	28,381	$1.13M
99212	Office or other outpatient visit for the evaluation and management of an established patient, straightforward	10%	56,878	50,495	$1.10M
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	9.7%	8,646	7,498	$1.03M
62323		4.3%	3,989	3,223	$455K
99442		2.2%	8,036	6,561	$236K
99441		2.2%	11,624	9,321	$230K
99203	Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity	2.0%	3,974	3,461	$213K
27096		1.8%	937	759	$195K
99204	Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity	1.4%	1,864	1,650	$145K

41 more codes

J2704	Injection, propofol, 10 mg	<1%	7,569	$72K
J1040	Injection, methylprednisolone acetate, 80 mg	<1%	7,066	$56K
90832	Psychotherapy session, about 30 minutes	<1%	1,734	$45K
90791	Psychiatric diagnostic evaluation	<1%	546	$29K
J2250	Injection, midazolam hydrochloride, per 1 mg	<1%	2,111	$28K
J1030	Injection, methylprednisolone acetate, 40 mg	<1%	1,739	$18K
J3010	Injection, fentanyl citrate, 0.1 mg	<1%	3,744	$18K
A9279	Monitoring feature/device, stand-alone or integrated, any type, includes all accessories, components and electronics, not otherwise classified	<1%	6,560	$18K
J1100	Injection, dexamethasone sodium phosphate, 1 mg	<1%	7,557	$17K
64493		<1%	87	$12K
81025		<1%	2,151	$11K
96127		<1%	4,224	$11K
Q9966	Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml	<1%	6,557	$10K
96160		<1%	4,198	$9K
A4550	Surgical trays	<1%	6,662	$8K
64635		<1%	29	$8K
A4556	Electrodes, (e.g., apnea monitor), per pair	<1%	3,382	$8K
99443		<1%	175	$7K
90792	Psychiatric diagnostic evaluation with medical services	<1%	142	$7K
62321		<1%	39	$6K
90833	Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on)	<1%	269	$6K
J3490	Unclassified drugs	<1%	17,702	$6K
64636		<1%	47	$5K
A4930	Gloves, sterile, per pair	<1%	6,608	$2K
99202	Office or other outpatient visit for the evaluation and management of a new patient, straightforward	<1%	54	$2K
64494		<1%	30	$2K
A4247	Betadine or iodine swabs/wipes, per box	<1%	208	$802.77
20553		<1%	29	$754.13
76942		<1%	15	$587.91
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	19	$483.05
82962		<1%	253	$444.05
82627		<1%	20	$434.83
77003		<1%	89	$366.25
82533		<1%	20	$318.80
A4209	Syringe with needle, sterile 5 cc or greater, each	<1%	2,229	$298.99
82607		<1%	19	$276.03
J7040	Infusion, normal saline solution, sterile (500 ml = 1 unit)	<1%	374	$246.54
83525		<1%	16	$164.85
A4215	Needle, sterile, any size, each	<1%	3,124	$129.73
36415	Collection of venous blood by venipuncture	<1%	20	$51.18
J0171	Injection, adrenalin, epinephrine, 0.1 mg	<1%	17	$2.52

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialNORMAN, ROBERT (OWNER/PRESIDENT)

Same official

Other billing entities under NORMAN, ROBERT

Full network →

Provider	Location	Paid
Robert A. Norman, D.O., P.A.	Tampa, FL	$595K
Anesthesia & Pain Specialists of Bowling Green PLC	Bowling Green, KY	$307K
Dermatology Healthcare, LLC	Tampa, FL	$122K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.